Duloxetine Capsule, Delayed Release
Product Images NDC 60760-462

12 FDA label images from St Mary's Medical Park Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 60760-462). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Duloxetine Structure)

Structure (Duloxetine Structure)
Chemical structure of duloxetine hydrochloride, showing the molecular arrangement including a naphthalene group, a thiophene ring, and an amine hydrochloride side chain.*
FDA Label Image

Figure1 (Duloxetine Fig1)

Figure1 (Duloxetine Fig1)
A line chart comparing the proportion of patients with relapse over time in days from randomization between placebo and Duloxetine treatment groups. The chart shows relapse proportions on the vertical axis and time in days on the horizontal axis, demonstrating different relapse rates between placebo and Duloxetine over approximately 200 days.*
FDA Label Image

Figure2 (Duloxetine Fig2)

Figure2 (Duloxetine Fig2)
A Kaplan-Meier survival curve chart comparing the proportion of patients with relapse over time (days) from randomization between two treatments: Duloxetine and placebo. The x-axis shows time in days, ranging from 0 to 300, and the y-axis shows the proportion of patients with relapse, ranging from 0 to 1. The Duloxetine group shows a consistently lower relapse proportion than the placebo group.*
FDA Label Image

Figure3 (Duloxetine Fig3)

Figure3 (Duloxetine Fig3)
A line chart showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at various dosages and placebo. The chart includes four lines representing Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, illustrating comparative patient improvement performance across pain improvement percentages from greater than 0% to 100%.*
FDA Label Image

Figure4 (Duloxetine Fig4)

Figure4 (Duloxetine Fig4)
A line graph depicting percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. The graph shows trends in pain improvement across these treatment groups over increasing pain improvement percentages.*
FDA Label Image

Figure5 (Duloxetine Fig5)

Figure5 (Duloxetine Fig5)
A line graph depicting percent improvement in pain from baseline on the x-axis against the percentage of patients improved on the y-axis. The legend identifies three lines: Duloxetine 60mg twice daily, Duloxetine 60mg once daily, and placebo. The graph compares patient improvement percentages across different pain improvement thresholds.*
FDA Label Image

Figure6 (Duloxetine Fig6)

Figure6 (Duloxetine Fig6)
A line graph comparing the percentage of patients improved by percent improvement in pain from baseline. It includes data for Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis shows the percentage of patients improved (0 to 100%).*
FDA Label Image

Figure7 (Duloxetine Fig7)

Figure7 (Duloxetine Fig7)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows two data series: Duloxetine 60 mg once daily and placebo, with Duloxetine generally showing higher patient improvement across various pain improvement percentages.*
FDA Label Image

Figure8 (Duloxetine Fig8)

Figure8 (Duloxetine Fig8)
A line graph comparing the percentage of patients improved across different levels of percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement intervals from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines represent the data: one for Duloxetine and one for placebo, showing higher improvement percentages for Duloxetine at most points.*
FDA Label Image

Figure9 (Duloxetine Fig9)

Figure9 (Duloxetine Fig9)
A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines display outcomes: Duloxetine has higher patient improvement percentages across most pain improvement ranges compared to placebo.*
FDA Label Image

Figure10 (Duloxetine Fig10)

Figure10 (Duloxetine Fig10)
A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The vertical axis shows percentage of patients improved from 0 to 100, and the horizontal axis shows percent improvement in pain from baseline ranging from >0 to 100. Duloxetine consistently shows a higher percentage of patient improvement across all pain improvement levels compared to placebo.*
FDA Label Image

462 (Duloxetine Dr 60mg 60ct 60760 462 60)

462 (Duloxetine Dr 60mg 60ct 60760 462 60)
Label for Duloxetine Delayed-Release Capsules 60 mg by St Mary's Medical Park Pharmacy, packaged in a quantity of 60. The label includes dosage form, strength, manufacturer (Ajanta Pharma Limited, India), and storage instructions. It also warns to dispense the accompanying Medication Guide and keep the product tightly sealed and out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.